Peptides for Depression & Mood Disorders

How peptide Targets Peptides for Depression

Selank is a synthetic analog of the immunomodulatory peptide tuftsin, developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. It has demonstrated anxiolytic and antidepressant-like effects in both animal models and Russian clinical studies. Its mechanism of action involves modulation of GABAergic neurotransmission — selank enhances the inhibitory effects of GABA without producing the sedation, tolerance, or dependence associated with benzodiazepines. Additionally, selank influences serotonin metabolism, increasing serotonin levels in specific brain regions, and reduces the expression of inflammatory cytokines (IL-6) that are increasingly recognized as contributors to depression. In Russian clinical practice, selank is approved as an anxiolytic, and clinical studies report improvements in anxiety and depressive symptoms in patients with generalized anxiety disorder.

Semax, a synthetic ACTH(4-10) analog, targets depression through a different primary mechanism: upregulation of brain-derived neurotrophic factor (BDNF). Reduced BDNF levels are one of the most replicated findings in depression research, and BDNF restoration is thought to underlie the therapeutic effects of both SSRIs and ketamine. Semax increases BDNF expression in the hippocampus and prefrontal cortex — regions central to mood regulation and cognitive function. It also modulates dopaminergic signaling, which is relevant to anhedonia (the inability to experience pleasure), a core depression symptom poorly addressed by standard SSRIs. Russian clinical studies report efficacy in cognitive impairment following stroke, with mood improvement as a secondary finding, but no Western randomized controlled trial has specifically evaluated semax for major depressive disorder.

Pinealon is a tripeptide (Glu-Asp-Arg) developed by the Khavinson group in St. Petersburg as part of the bioregulatory peptide research program. It has demonstrated neuroprotective effects in cellular and animal models, with proposed mechanisms including regulation of gene expression in pinealocytes and neurons, modulation of melatonin synthesis pathways, and protection against oxidative stress-induced neuronal damage. Melatonin-depression connections are well-established — disrupted circadian rhythms and sleep architecture are both causes and consequences of depressive episodes. However, pinealon's evidence base is limited primarily to in vitro studies and Russian-language preclinical publications, making it the least clinically validated compound on this list.

NA-selank-amidate is a modified form of selank with an N-acetyl group and C-terminal amide modification designed to improve metabolic stability and potentially enhance CNS penetration after intranasal administration. The modifications extend the peptide's half-life and may improve bioavailability across the blood-brain barrier. It retains selank's GABAergic and anti-inflammatory mechanisms while theoretically providing a more sustained pharmacological effect. However, NA-selank-amidate has less published clinical data than selank itself — most evidence is extrapolated from selank research with the assumption that enhanced stability translates to improved efficacy.